Following Contemporary Drug Synthesis and The Art of Drug Synthesis (Wiley, 2004 and 2007), two well-received works, is this new book that demystifies the process of modern drug discovery for practitioners and students. An enhanced introduction covers areas such as background, pharmacology, SAR, PK/PD, efficacy, and safety. Focusing on the advantages of process synthesis versus the discovery synthetic route, Modern Drug Synthesis features authoritative coverage by distinguished editors and authors (some chapter ...
See more details below
Modern Drug Synthesis

Available on NOOK devices and apps  
  • NOOK Devices
  • Samsung Galaxy Tab 4 NOOK 7.0
  • Samsung Galaxy Tab 4 NOOK 10.1
  • NOOK HD Tablet
  • NOOK HD+ Tablet
  • NOOK eReaders
  • NOOK Color
  • NOOK Tablet
  • Tablet/Phone
  • NOOK for Windows 8 Tablet
  • NOOK for iOS
  • NOOK for Android
  • NOOK Kids for iPad
  • PC/Mac
  • NOOK for Windows 8
  • NOOK for PC
  • NOOK for Mac
  • NOOK for Web

Want a NOOK? Explore Now

NOOK Book (eBook)
BN.com price
(Save 42%)$129.00 List Price
Note: This NOOK Book can be purchased in bulk. Please email us for more information.


Following Contemporary Drug Synthesis and The Art of Drug Synthesis (Wiley, 2004 and 2007), two well-received works, is this new book that demystifies the process of modern drug discovery for practitioners and students. An enhanced introduction covers areas such as background, pharmacology, SAR, PK/PD, efficacy, and safety. Focusing on the advantages of process synthesis versus the discovery synthetic route, Modern Drug Synthesis features authoritative coverage by distinguished editors and authors (some chapter authors are the actual inventor of the drug) of twenty different drug molecules.
Read More Show Less

Editorial Reviews

From the Publisher
"All chapters are very well written, and the used schemes and tables are conveniently arranged. The information and explanations given are strengthened by well-chosen examples and so the reader can easily follow the discussion. The comprehensive referenced literature placed at the end of each chapter enables further reading, and a detailed keyword index in combination with a logically structured Table of Content allows fast access to the topic of interest." (ChemMedChem, 2010)
Read More Show Less

Product Details

  • ISBN-13: 9781118701249
  • Publisher: Wiley
  • Publication date: 3/27/2013
  • Series: Wiley Series on Drug Synthesis
  • Sold by: Barnes & Noble
  • Format: eBook
  • Edition number: 1
  • File size: 13 MB
  • Note: This product may take a few minutes to download.

Meet the Author

JIE JACK LI is a chemist at Bristol-Myers Squibb Company in Wallingford, Connecticut. He is the coauthor of various books, including Palladium in Heterocyclic Chemistry, Name Reactions: A Collection of Detailed Reaction Mechanisms and Synthetic Applications, Name Reactions in Heterocyclic Chemistry, Contemporary Drug Synthesis, The Art of Drug Synthesis, Name Reactions for Functional Group Transformations, Name Reactions for Homologations, Parts 1 and 2, and Name Reactions for Carbocyclic Ring Formations.

DOUGLAS JOHNSON is a medicinal chemist and project leader at Pfizer in Groton, Connecticut. He is a coauthor on more than forty publications and patents, including the books The Art of Drug Synthesis and Contemporary Drug Synthesis.

Read More Show Less

Table of Contents



I. Infectious Diseases.

Chapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor (Julianne A. Hunt).

1.1 Background.

1.2 Pharmacology.

1.3 Structure-Activity Relationship (SAR).

1.4 Pharmacokinetics and Drug Metabolism.

1.5 Efficacy and Safety.

1.6 Syntheses.

1.7 References.

Chapter 2. Maraviroc (Selzentry), The First-in-class CCR5 Antagonist for the Treatment of HIV (David Price).

2.1 Background.

2.2 Structure-Activity Relationship (SAR).

2.3 Pharmacokinetics and Safety.

2.4 Syntheses.

2.5 References.

Chapter 3. Darunavir (Prezista), A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV (Arun K. Ghosh and Cuthbert D. Martyr).

3.1 Background.

3.2 Pharmacology.

3.3 Structure-Activity Relationship (SAR).

3.4 Pharmacokinetics and Drug Metabolism.

3.5 Efficacy and Safety.

3.6 Syntheses.

3.7 References.

II. Cancer.

Chapter 4. Decitabine (Dacogen), A DNA Methyltransferase Inhibitor for Cancer (Jennifer A. Van Camp).

4.1 Background.

4.2 Pharmacology.

4.3 Structure-Activity Relationship (SAR).

4.4 Pharmacokinetics and Drug Metabolism.

4.5 Efficacy and Safety.

4.6 Syntheses.

4.7 References.

Chapter 5. Capecitabine (Xeloda), An Oral Chemotherapy Agent (R. Jason Herr).

5.1 Background.

5.2 Pharmacology.

5.3 Structure-Activity Relationship (SAR).

5.4 Pharmacokinetics and Efficacy.

5.5 Syntheses.

5.6 References.

Chapter 6. Sorafenib (Nexavar), A Multi-kinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma (Shuanghua Hu).

6.1 Background.

6.2 Pharmacology.

6.3 Structure-Activity Relationship (SAR).

6.4 Pharmacokinetics and Drug Metabolism.

6.5 Efficacy and Safety.

6.6 Syntheses.

6.7 References.

Chapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor (Martin Pettersson).

7.1 Background.

7.2 Discovery and Development.

7.3 Syntheses.

7.3.1 Discovery Route.

7.3.2 Process Route.

7.4 References.

Chapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor (Benjamin S. Greener and David S. Millan).

8.1 Background.

8.2 Pharmacology.

8.3 Structure-Activity Relationship (SAR).

8.4 Pharmacokinetics and Drug Metabolism.

8.5 Efficacy and Safety.

8.6 Syntheses.

8.7 References.

Chapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer (Ji Zhang and Jie Jack Li).

9.1 Background.

9.2 Pharmacology.

9.3 Structure?Activity Relationship (SAR).

9.4 Pharmacokinetics and Drug Metabolism.

9.5 Efficacy and Safety.

9.6 Syntheses.

9.7 Other VEGFR Inhibitors in Development: Vandetanib and Cediranib.

9.8 References.

III. Cardiovascular and Metabolic Diseases.

Chapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes (Scott D. Edmondson, Feng Xu, and Joseph D. Armstrong III).

10.1 Background.

10.2 Pharmacology.

10.3 Structure-Activity Relationship (SAR).

10.4 Pharmacokinetics and Drug Metabolism.

10.5 Efficacy and Safety.

10.6 Syntheses.

10.7 References.

Chapter 11. Aliskiren (Tekturna), The First-in-class Renin Inhibitor for Hypertension (Victor J. Cee).

11.1 Background.

11.2 Pharmacology.

11.3 Structure-Activity Relationship (SAR).

11.4 Pharmacokinetics and Drug Metabolism.

11.5 Efficacy and Safety.

11.6 Syntheses.

11.7 References.

Chapter 12. Vernakalant (Kynapid), An Investigational Drug for the Treatment of Atrial Fibrillation (David L. Gray).

12.1 Background.

12.2 Pharmacology.

12.3 Structure-Activity Relationship (SAR).

12.4 Pharmacokinetics and Drug Metabolism.

12.5 Efficacy and Safety.

12.6 Syntheses.

12.7 References.

Chapter 13. Conivaptan (Vaprisol), Vasopressin V1a and V2 Antagonist for Hyponatremia (Brian A. Lanman).

13.1 Background.

13.2 Pharmacology.

13.3 Structure-Activity Relationship (SAR).

13.4 Pharmacokinetics and Drug Metabolism.

13.5 Efficacy and Safety.

13.6 Syntheses.

13.7 References.

Chapter 14. Rivaroxaban (Xarelto), A Factor Xa Inhibitor for the Treatment of Thrombotic Events (Ji Zhang and Jason Crawford).

14.1 Background.

14.2 Pharmacology.

14.3 Structure?Activity Relationship (SAR).

14.4 Pharmacokinetics and Drug Metabolism.

14.5 Efficacy and Safety.

14.6 Syntheses.

14.7 Compounds in Development: Apixaban and Otamixaban.

14.8 References.

Chapter 15. Endothelin Antagonists for the Treatment of Pulmonary Arterial Hypertension (David Edmonds).

15.1 Background.

15.2 Treatment of PAH.

15.3 Endothelin Antagonists.

15.4 Synthesis of Bosentan.

15.5 Synthesis of Sitaxsentan.

15.6 Synthesis of Ambrisentan.

15.7 Conclusion.

15.8 References.

IV. Central Nervous System Diseases.

Chapter 16. Varenicline (Chantix), An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation (Jotham W. Coe, Frank R. Busch and Robert A. Singer).

16.1 Background.

16.2 Discovery Chemistry Program.

16.3 Pharmacology.

16.4 Pharmacokinetics and Drug Metabolism.

16.5 Efficacy and Safety.

16.6 Syntheses.

16.7 References.

Chapter 17. Donepezil, Rivastigmine, Galantamine: Cholinesterase Inhibitors for Alzheimer's Disease (Subas Sakya and Kapil Karki).

17.1 Background.

17.2 Pharmacology.

17.3 Structure?Activity Relationship (SAR).

17.4 Pharmacokinetics and Drug Metabolism.

17.5 Efficacy and Safety.

17.6 Synthesis of Donepezil.

17.7 Synthesis of Rivastigmine.

17.8 Synthesis of Galantamine.

17.9 References.

Chapter 18. Aprepitant (Emend), A NK1 Receptor Antagonist for the Treatment of Post-chemotherapy Emesis (John A. Lowe, III).

18.1 Background.

18.2 In Vitro Pharmacology and Structure-Activity Relationships.

18.3 In Vivo Pharmacology.

18.4 Pharmacokinetics and Drug Metabolism.

18.5 Efficacy and Safety.

18.6 Syntheses.

18.7 References.

Chapter 19. Armodafinil (Nuvigil), A Psychostimulant for the Treatment of Narcolepsy (Ji Zhang and Jason Crawford).

19.1 Background.

19.2 Pharmacology.

19.3 Pharmacokinetics and Drug Metabolism.

19.4 Efficacy and Safety.

19.5 Synthesis.

19.6 References.

V. Miscellaneous.

Chapter 20. Raloxifene (Evista), A Selective Estrogen Receptor Modulator (SERM) (Marta Piñeiro-Núñez).

20.1 Background.

20.2 Mechanism of Action.

20.3 Pharmacokinetics and Drug Metabolism.

20.4 Efficacy and Safety.

20.5 Syntheses.

20.6 References.

Chapter 21. Latanoprost (Xalatan), A Prostanoid FP Agonist for Glaucoma (Sajiv K. Nair and Kevin E. Henegar).

21.1 Background.

21.2 Syntheses.

21.3 References.


Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star


4 Star


3 Star


2 Star


1 Star


Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation


  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)